This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.
MagnetisMM-3 (trial ongoing) is an open-label, global, multicentre, non-randomised Phase 2 study evaluating ELREXFIO® monotherapy in patients with relapsed or refractory multiple myeloma (RRMM), refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-CD38 monoclonal antibody.1
The primary endpoint is objective response rate (ORR) as assessed by blinded independent central review (BICR). Key secondary endpoints include: minimal residual disease (MRD) negativity rate (10-5), time to response (TTR), duration of response (DoR), progression-free survival (PFS), complete response rate (CRR), and safety.1
Adapted from ELREXFIO® Summary of Product Characteristics.1
*The dosing interval was changed from QW to Q2W in patients who achieved an IMWG response category of partial response or better with responses persisting for at least 2 months.1
| BCMA-directed therapy-naïve patients (n=123) | ||
|---|---|---|
| All grades, n (%) | Grade 3/4, n (%) | |
| Any TEAE | 123 (100) | 87 (70.7) |
| Haematologic | ||
| Anaemia | 60 (48.8) | 46 (37.4) |
| Neutropenia | 60 (48.8) | 60 (48.8) |
| Thrombocytopenia | 38 (30.9) | 29 (23.6) |
| Lymphopenia | 33 (26.8) | 31 (25.2) |
| Non-haematologic | ||
| CRS | 71 (57.7) | 0 |
| Diarrhoea | 52 (42.3) | 2 (1.6) |
| Fatigue | 45 (36.6) | 4 (3.3) |
| Decreased appetite | 41 (33.3) | 1 (0.8) |
| Pyrexia | 37 (30.1) | 5 (4.1) |
| COVID-19 related* | 36 (29.3)† | 19 (15.4) |
| Injection site reaction | 33 (26.8) | 0 |
| Nausea | 33 (26.8) | 0 |
| Hypokalaemia | 32 (26.0) | 13 (10.6) |
| Cough | 31 (25.2) | 0 |
| Headache | 29 (23.6) | 0 |
Adapted from Lesohkin AM, et al. Nature Med. 2023.2
Data cutoff: 14 March 2023 (except from CRS and ICANS data which were 12 January 2023).(Median follow-up was 14.7 months [range 0.2-25.1 months])
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024